Loading...
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome
Reduction of APL antibodies by immunoadsorption may be a lifesaving therapy for the management of DAH with high titer of APL antibodies. Autologous HSCT may be a valid treatment option in patients with primary APS and no response to standard immunosuppressive therapy.
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6737408/ https://ncbi.nlm.nih.gov/pubmed/31506284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000465 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|